Dernières nouvelles pour Cronos Group (NASDAQ:CRON) Stock

Cronos Group

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Cronos Group Inc

Cryptocean

CRONOS GROUP ORD

Crona Corp

News

Financing

XCUR

Exicure Enters Into Purchase Agreements For $1.3M And $8.7M Equity Financing

Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.67) by 76.05 percent. The company reported quarterly sales of $5.863 million which missed the analyst consensus estimate of $6.000 million by 2.28 percent. This is a 218.30 percent increase over sales of $1.842 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SYTA

Siyata Mobile Q3 2024 GAAP EPS $(0.40) Beats $(1.67) Estimate, Sales $5.863M Miss $6.000M Estimate

Exicure Q3 EPS $(0.57) Up From $(3.04) YoY

WIIM

ADGM

Adiago Medical Holdings shares are trading after the company reported better-than-expected Q3 financial results.

Contracts

AXON

Axon Wins Federal Government Contract To Supply Royal Canadian Mounted Police With Body-Worn Cameras; Terms Not Disclosed

Outlook
Post management expects Adjusted EBITDA for fiscal year 2025 to be between $1,410-$1,460 million. Post management expects fiscal year 2025 capital expenditures to range between $380-$420 million, which includes Post Consumer Brands investment in network optimization and pet food safety and capacity, for aggregate expenditures of $90-$100 million. This also includes Foodservice investment in the completion of the Norwalk, Iowa precooked egg facility expansion and continued cage-free egg facility expansion, for aggregate expenditures of $80-$90 million.
Post provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted EBITDA non-GAAP guidance measure to the most directly comparable GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for income/expense on swaps, net, gain/loss on extinguishment of debt, net, integration and transaction costs, mark-to-market adjustments on commodity and foreign exchange hedges, mark-to-market adjustments and impairments on equity securities and investments, equity method investment adjustment and other charges reflected in Post's reconciliations of historical numbers, the amounts of which, based on historical experience, could be significant. For additional information regarding Post's non-GAAP measures, see the related explanations presented under "Use of Non-GAAP Measures."

Guidance

POST

Post Management Expects Adjusted EBITDA For FY25 To Be Between $1.410B-$1.460B; Capital Expenditures To Range Between $380M-$420M

BRLS

Borealis Foods Q3 EPS $(0.23) Up From $(0.61) YoY, Net Revenue $7.69M Down From $7.72M YoY

LGCY

Legacy Education Q1 EPS $0.21 Up From $0.11 YoY: Revenue $14.005M Up From $10.366M YoY

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

Price Target

Analyst Ratings

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

Post Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.23 by 24.39 percent. This is a 6.13 percent decrease over earnings of $1.63 per share from the same period last year. The company reported quarterly sales of $2.01 billion which beat the analyst consensus estimate of $1.97 billion by 2.29 percent. This is a 3.34 percent increase over sales of $1.95 billion the same period last year.

Post Hldgs Q4 Adj $1.53 Beats $1.23 Estimate, Sales $2.01B Beat $1.97B Estimate

CEA Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEAD#NASDAQ">CEAD</a>) reported quarterly losses of $(0.94) per share. This is a 21.67 percent increase over losses of $(1.20) per share from the same period last year. The company reported $391.00 thousand in sales this quarter. This is a 57.20 percent decrease over sales of $913.57 thousand the same period last year.

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CEA Industries Q3 EPS $(0.94) Up From $(1.20) YoY, Sales $391.00K Down From $913.57K YoY

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Equities

Government

Regulations

Health Care

Politics

Markets

Movers

MRNA

NVAX

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

Trading Ideas

BRK/A

FWONA

FWONK

SIRI

Berkshire Hathaway 13F Shows Exited Position In Liberty Media Corp Series C, Previously Holding 70M Shares, Worth $1.55B; Exited Position In Liberty Media Corp Series A, Previously Holding 35.18M Shares, Worth $779.3M; Exited Position In Floor & Decor Holdings, Previously Holding 3.98M Shares, Worth $395.4M; Exited Position In Sirius XM Holdings Inc, Previously Holding 132.88M Shares, Worth $376M

NVFY

Nova Lifestyle shares are trading higher after the company announced better-than-expected Q3 financials.

TSSI

TSS Q3 EPS $0.10 Up From $0.01 YoY; Revenue $70.068M Up From $8.880M YoY

Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.08) by 175 percent. This is a 26.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $64.52 million which missed the analyst consensus estimate of $68.61 million by 5.97 percent. This is a 2.60 percent decrease over sales of $66.24 million the same period last year.

FLNT

Fluent Q3 Adj $(0.22) Misses $(0.08) Estimate, Sales $64.52M Miss $68.61M Estimate

If you've ever regretted eating that second gummy because the first one took forever to kick in, you're not alone. From unpredictable highs to hours of couch lock, the edible experience can be a minefield of bad trips. But Azuca is on a mission to change all that.
With a revolutionary whole-plant infusion process, Azuca's food-tech innovation standardizes the high. No solvents, no distillates—just a fast-acting, full-spectrum experience that finally delivers on the promise of predictable, enjoyable edibles.&nbsp;
In an exclusive interview with Benzinga Cannabis, CEO Kim Sanchez Rael shared how this innovation isn't just a win for consumers, it's a game changer for cannabis investors and edibles brands looking to stand out in a crowded market. 
"We've eliminated the typical pitfalls of the edibles segment," said Rael. "Our process offers a cleaner, more efficient path to product differentiation and profitability, all while delivering a superior experience to the end consumer."
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">A New Chapter In Edibles: Whole-Plant Infusion Without Extractions</h3>
One of the most significant breakthroughs from Azuca is its ability to <a href="https://feeds2.benzinga.com/markets/cannabis/24/04/38473652/inside-gr-ns-marijuana-edibles-factory-what-can-we-learn-about-choco-nomics-and-multi-state-expa">create edibles</a> using the entire cannabis flower without relying on extractions like distillate or resin. Traditional edible production involves extracting THC from the cannabis plant, often using solvents.&nbsp;
Meanwhile,<a href="https://www.benzinga.com/markets/cannabis/24/04/38093020/exclusive-why-wait-azuca-obx-speed-up-cannabis-access"> Azuca </a>utilizes the entire flower, delivering what Rael called a true "entourage effect" in an edible format. "We've made it possible to infuse edibles directly with cannabis flower, bypassing the need for any extraction. This means consumers get the full spectrum of the plant's compounds—<a href="https://www.benzinga.com/general/biotech/24/05/38626097/why-does-tangie-smell">cannabinoids, terpenes, and flavonoids</a>—in a consistent format. It's the closest experience to smoking the plant but without the need to inhale."
<h3 class="wp-block-heading">Ending The Bad Trip: Predictable Highs</h3>
Traditional<a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40520617/detroits-first-cannabis-bakery-and-cafe-opens-soon-thc-cbd-infused-delights-await"> edibles</a> can take anywhere from 1 to 2 hours to kick in, leading many users to consume more than they should in frustration. The slow metabolization of THC in the liver can also produce a different, often more intense form of THC, which can result in a heavier, sedative effect—what the industry colloquially calls "couch lock."
Azuca's proprietary technology addresses this problem head-on. By encapsulating cannabis oil molecules in a starch-based shell, Azuca ensures that the cannabinoids are transformed into water-soluble compounds.&nbsp;
The encapsulation process allows the active ingredients to be absorbed rapidly in the mouth and upper digestive tract, bypassing the liver's delayed metabolization.
"Our technology delivers onset times as quick as 5 to 15 minutes," explained Rael. "This fast absorption not only prevents overconsumption but also offers a more predictable and sessionable experience, similar to smoking but in an <a href="https://feeds2.benzinga.com/markets/cannabis/24/10/41388261/revolutionizing-cannabis-edibles-ascends-new-thc-cannabinoid-blends-now-available-in-this-east-c">edible form</a>."
The encapsulation process also preserves the chemical integrity of the<a href="https://www.benzinga.com/markets/cannabis/23/12/36394288/cannabis-2024-experts-weigh-in-what-to-expect-from-dc-and-business-outlook-exciting-point-in-tim"> cannabinoids</a>, meaning that consumers experience THC in its Delta-9 form rather than the more intense 11-hydroxy-THC.&nbsp;
"We've effectively standardized the high," said Rael. "Gone are the days of nausea, anxiety, and unpredictable effects. Our products deliver a consistent, uplifting experience every time." While Azuca's technology aims to deliver a standardized, predictable experience,<a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40121179/cannabis-edibles-gone-wrong-high-flyers-door-forcing-drama-and-assault-force-emergency-landing"> individual responses can still vary</a> based on dosage, personal tolerance and other factors.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41948483/give-me-a-break-new-york-times-says-actor-jim-belushi-as-he-defends-cannabis-criticizes-big-pharma-food-industry"> &#8216;Give Me A Break, New York Times,&#8217; Says Actor Jim Belushi As He Defends Cannabis, Criticizes Big Pharma, Food Industry</a>
<h3 class="wp-block-heading">Starch Encapsulation: The Vanguard Of Food-Tech In Cannabis</h3>
Azuca's innovations are rooted in cutting-edge food technology, specifically the use of modified starches for encapsulating oil-based cannabinoids. Traditional methods of infusing <a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40471578/mike-tysons-new-line-of-weed-gummies-now-available-in-colorado-heres-where-to-find-them-and-win-">edibles with THC</a> involve the use of sticky, viscous distillate, which can lead to significant waste and degradation of potency during the cooking process. Distillates are prone to transfer loss, cannabis oil sticking to mixing equipment, and oxidation from exposure to heat.
Azuca's encapsulation technique solves these issues. The proprietary starch coating not only makes the cannabinoids water-friendly but also prevents them from sticking to equipment, reducing waste.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="731" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-731x1024.jpg" alt="" class="wp-image-646421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-731x1024.jpg 731w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-214x300.jpg 214w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-768x1076.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew.jpg 771w" sizes="(max-width: 731px) 100vw, 731px" /><figcaption class="wp-element-caption">Kim Sanchez Rael &#8211; headshot-cred_ Kim Jew</figcaption></figure>
According to Rael, the process reduces active ingredient loss by up to 20% during manufacturing, translating to significant cost savings for producers.
"Our starch encapsulation process is a game changer for the industry," Rael noted. "It protects the cannabinoids from degradation, ensuring potency, and allows for seamless integration into any <a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40225540/summer-sizzles-with-thc-infused-beverages-market-report-reveals-top-selling-weed-drinks-in-u-s">edible product</a> without the need for additional extraction or emulsification equipment."
<h3 class="wp-block-heading">Scale And Market Reach</h3>
Azuca's business model is built on licensing its technology to cannabis brands and manufacturers. This approach has allowed the company to quickly <a href="https://feeds2.benzinga.com/markets/cannabis/24/06/39538627/from-local-startup-to-cannabis-edibles-powerhouse-cameron-saner-on-pushing-kosmik-brands-to-infi">scale and penetrate multiple markets</a> across the U.S. and Canada. The process is straightforward: Azuca supplies its proprietary Activator, a non-infused precursor, which manufacturers can easily mix with their cannabis input—whether it's distillate, live resin, or whole flower.
"Our model is designed to be scalable for any size operation," she said. "We have over 100 licensing agreements and have infused close to 2 billion milligrams of cannabinoids since our launch."
The Activator is available in different formulations tailored for various product types, including gummies, beverages, and chocolates. "We've made it easy for our partners to integrate our technology into their existing processes, without the need for heavy equipment or extensive training," Rael explained.
Read Also: <a href="https://www.benzinga.com/news/24/09/40941818/how-this-cheese-aging-tech-is-boosting-profits-for-cannabis-growers-stop-throwing-cheddar-out-the-do">How This Cheese-Aging Tech Is Boosting Profits For Cannabis Growers: Stop Throwing Cheddar Out The Door</a>
<h3 class="wp-block-heading">Financial Impact: Reduced Waste, Increased Profit Margins</h3>
Azuca's technology offers significant financial advantages for manufacturers. The reduction in waste during production not only improves efficiency but also boosts profitability. Products made with Azuca's technology often command a premium price in the marketplace.&nbsp;
"Consumers are willing to pay more for a product that offers a predictable, high-quality experience," said Rael. "We've seen premium pricing of 20% or more for fast-acting edibles, and up to a 50% premium for products that combine fast onset with functional effects like sleep or relaxation."
<h3 class="wp-block-heading">Beyond The Bud</h3>
While Azuca is focused on the cannabis industry, Rael sees potential applications for their encapsulation technology in other sectors, such as nutraceuticals. "This is fundamentally a substance delivery system. We're taking molecules that are difficult to metabolize and making them easy for the body to absorb. The same principles could apply to vitamins, supplements, and other active ingredients outside of cannabis."
By eliminating the need for extractions and delivering a fast, predictable, and enjoyable experience, Azuca is paving the way for a new generation of cannabis edibles.
"We're driven by innovation," Rael concluded. "Our mission is to raise the bar for what edibles can be and to provide a better experience for both consumers and manufacturers alike. This is just the beginning."
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40972472/x-rays-microwaves-and-now-what-this-company-freezes-weed-at-320-f-to-kill-mold-and-save-a-ton">X-Rays, Microwaves, And Now What? This Company Freezes Weed At -320°F To Kill Mold And Save A Ton</a>

Cannabis

Exclusives

Interview

Was The Whole Gummy Too Much? Azuca Solves The Cannabis Edibles Problem With Food-Tech

ALRN

Aileron Therapeutics Q3 EPS $(0.27) Beats $(0.41) Estimate

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

ENLV

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Kidpik (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIK#NASDAQ">PIK</a>) reported quarterly losses of $(0.45) per share. This is a 62.5 percent increase over losses of $(1.20) per share from the same period last year. The company reported $1.00 million in sales this quarter. This is a 70.49 percent decrease over sales of $3.39 million the same period last year.

Kidpik Q3 EPS $(0.45) Up From $(1.20) YoY, Sales $1.00M Down From $3.39M YoY

Avoid Canopy Growth

This week, several major companies will be reporting earnings. Among them are Alibaba (BABA), Walt Disney (DIS), Plug Power (PLUG), Cisco Systems (...

Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024

Here's the major earnings before the open tomorrow

Reports Q3 revenue $34.264M vs $24.810M last year. "Our results this quarter demonstrate that our long-term strategy is working. With record net re...

Cronos Group reports Q3 EPS 2c, consensus (1c)

Earnings Snapshot: Cronos reports surprise profit as Q3 revenue rises by 38% Y/Y

Cronos Group Inc. (CRON) Q3 2024 Earnings Call Transcript

Cronos stock jumps 11% on Q3 earnings report

Cronos Group (TSE:CRON) has released an update. Cronos Group reported a significant 38% increase in Q3 2024 net revenue, reaching $34.3 million, dr...

Cronos Group Sees Revenue Surge and Market Dominance

In the third quarter, Cronos' Spinach brand became the best-selling cannabis brand in the Canadian adult-use market and their Peace Naturals brand held a top spot in the Israeli medical market.

Cronos Group Q3 Financials; Total Net Revenue Was Up; International Sales Were Up 29%

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

AAWH

ACTG

AGEN

AMAT

AMTX

ASTS

ATAI

AUTL

AXSM

AYRWF

BABA

BAYZF

BIOX

BITF

BLDE

BNGO

BWAY

BXSL

CAMT

CANN

CBAT

CCLD

CGEN

CMPS

CRLBF

CRON

CSCO

CVAC

CVSI

CYBN

DAVA

ENVB

EVGO

FLNG

FOUR

GENI

GLNG

GOEV

GRWG

HUYA

IMCC

KOPN

LAZR

LEGN

LFWD

MARA

MEDIF

MIRM

NLCP

NSPR

ONON

PLUG

RAIL

RGEN

RGTI

RKLB

RLMD

ROIV

SATS

SDGR

SFTBY

SHFS

SHLS

SHOP

SLVM

SOHO

SOHU

SOUN

SPHR

SPOT

STNE

SWKS

TCNNF

TIGR

TLRY

VERI

VREOF

VRNOF

VXRT

WKHS

ZLAB

Press Releases

General

Cronos Brand Spinach® Celebrates Summer with New Launches

Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders

U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist

Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024

Cronos Group Reports 2024 Second Quarter Results

Lord Jones® Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across Canada

Spinach® Is the Number One Cannabis Brand in Canada

Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

Comments

Cronos Group

Actualités

Dernières nouvelles pour Cronos Group (NASDAQ:CRON) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL